Alkermes plc to Post Q1 2026 Earnings of $0.43 Per Share, Zacks Research Forecasts (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for Alkermes in a research note issued on Wednesday, October 9th. Zacks Research analyst R. Department now anticipates that the company will earn $0.43 per share for the quarter, up from their previous estimate of $0.42. The consensus estimate for Alkermes’ current full-year earnings is $2.36 per share.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. The company had revenue of $399.13 million during the quarter, compared to analyst estimates of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The firm’s revenue was down 35.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 earnings per share.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price target on shares of Alkermes in a research note on Thursday. JPMorgan Chase & Co. upped their price target on Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a research note on Thursday, July 25th. TD Cowen assumed coverage on Alkermes in a research note on Monday, June 17th. They set a “buy” rating and a $34.00 price target for the company. Robert W. Baird increased their target price on Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, HC Wainwright increased their target price on Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Alkermes presently has a consensus rating of “Moderate Buy” and an average price target of $36.70.

Alkermes Stock Performance

Shares of NASDAQ:ALKS opened at $28.91 on Friday. The firm has a market capitalization of $4.89 billion, a PE ratio of 11.43, a P/E/G ratio of 0.56 and a beta of 0.46. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.99 and a quick ratio of 2.61. The business has a 50-day moving average of $27.61 and a two-hundred day moving average of $25.79. Alkermes has a 12 month low of $22.01 and a 12 month high of $32.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky lifted its holdings in Alkermes by 34.9% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 175,354 shares of the company’s stock worth $4,865,000 after buying an additional 45,400 shares during the last quarter. American International Group Inc. lifted its holdings in Alkermes by 9.1% during the 4th quarter. American International Group Inc. now owns 90,314 shares of the company’s stock worth $2,505,000 after buying an additional 7,503 shares during the last quarter. Twin Focus Capital Partners LLC bought a new position in Alkermes during the 4th quarter worth approximately $2,220,000. Wellington Management Group LLP lifted its holdings in Alkermes by 29.8% during the 4th quarter. Wellington Management Group LLP now owns 15,241,470 shares of the company’s stock worth $422,798,000 after buying an additional 3,494,678 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Alkermes by 1.0% during the 4th quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock worth $1,663,000 after buying an additional 572 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.